TCRs detect intracellularly processed peptide–MHC complexes rather than relying on abundant surface proteins, which makes them able to identify tumor cells expressing even low levels of antigen or those that have undergone partial antigen loss. This evidence concerns the gene HLA-C and neoplasm.